TOTAL: $247.922M

Company (Location)

Type OfFinancing

Number OfShares, Units Or Warrants (M)

AmountRaised(M)

Investors; Placement Agents; Details (Date)

AcelRx Pharmaceuticals Inc. (Redwood City, Calif.)

Loan

N/A

$7.2

AcelRx secured a $20M loan from Hercules Technology Growth Capital; it received $10M in the first tranche, but used $2.8M to repay a loan from Pinnacle Ventures LLC (7/5)

Anavex Life Sciences Corp. (Hoboken, N.J.)

Exercise of warrants

0.7W for 0.7S

$1 .575

Anavex raised $1.575M through the exercise of warrants (7/12)

Aradigm Corp. (Hayward, Calif.)

Private placement of common stock

25S

$4.75

Aradigm is selling 25M shares of common stock at 19 cents each to three existing shareholders, including those associated with First Eagle Investment Management LLC and Tavistock Life Sciences (7/7)

Cell Therapeutics Inc. (Seattle)

Private placement of preferred stock and warrants

17.647S and W for 8.82S

$30

Cell Therapeutics agreed to sell $30M shares of Series 13 preferred stock and warrants to six institutional investors; they are convertible into 17.647M shares, and warrants are good for up to 8.82M shares (7/5)

Celsion Corp. (Columbia, Md.)

Registered direct offering; a second registered direct offering and a private placement

2.1U; 3U and 1 .3U

$6.6; $13 and $5.4

Celsion raised $6.6M in the registered direct offering of 2.1M units at $3.1675 apiece, with each unit consisting of one common share and a five-year warrant to purchase 0.3 additional shares at an exercise price of $3.13; Rodman & Renshaw LLC acted as the exclusive placement agent (7/8); Celsion raised $18.4M total by offering 3M units priced at $4.2575 apiece, with each unit consisting of one share and one warrant to purchase 0.3 additional shares, and by selling 1.3M units for $4.27 apiece, with each unit consisting of one share and one warrant to purchase 0.4 additional shares; Rodman & Renshaw LLC acted as the sole placement agent (7/22)

Cytori Therapeutics Inc. (San Diego)

Equity purchase agreement

1.3S

$6

Cytori raised $6M through the agreement with Seaside 88 LP, which bought 1.3M common shares at $4.52 each (7/13)

Generex Biotechnology Corp. (Worcester, Mass.)

Securities purchase agreement

0.002575U

$2.575

Generex is raising $2.575M through the sale of 2,575 units priced at $1,000 apiece and consisting of one share of nonvoting Series A 9% convertible preferred stock and one warrant to purchase 100% of the shares of common stock issuable upon conversion (7/12)

Icagen Inc. (Research Triangle Park, N.C.)

Equity investment

8.3S

$49.8

Pfizer Inc. acquired about 8.3M shares in Icagen at $6 each, making it a majority shareholder (7/21)

Insite Vision Inc. (Alameda, Calif.)

Private placement

37S and W for 14.8S

$22.2

Insite raised $22.2M in the private placement; Piper Jaffray & Co. served as sole placement agent (7/14)

NanoViricides Inc. (West Haven, Conn.)

Private placement of Series B convertible preferred stock

0.25S

$2.5

NanoViricides raised $2.5M through the sale of 250,000 shares of Series B convertible preferred stock priced at $10 apiece to Seaside 88 LP (7/28)

Northwest Biotherapeutics Inc. (Bethesda, Md.)

Equity investment

N/A

$4.55

Northwest received a $4.55M equity investment by the Richard M. Schulze Family Foundation (7/11)

PharmaGap Inc. (Ottawa, Ont.)

Private placement of units

0.885U

C$0.5 ($0.522)

PharmaGap completed the initial close of a $521,975 private placement; it sold 884,500 units for C9 cents apiece, with each unit consisting of one common share and one two-year warrant to purchase an additional share at an exercise price of C14 cents (7/14)

Pharming Group NV (Leiden, the Netherlands)

Private placement of stock and warrants

29S

€3.2 ($4.55)

Pharming Group raised $4.55M in a private placement of stock and warrants, issuing 29M shares along with five-year warrants to purchase an additional 20.3M shares; Roth Capital Partners acted as the sole placement agent (7/22)

Protox Therapeutics Inc. (Vancouver, British Columbia)

Loan agreement

N/A

$15

Protox entered a $15M loan agreement with Oxford Finance LLC (7/19)

QRxPharma Ltd. (Sydney, Australia)

Private placement

N/A

A$35.4 ($38)

QRxPharma raised $38M through a placement and a 1-for-20 rights issue; RBS Morgans Corporate Ltd. and Bell Potter Securities Ltd. were joint lead managers on the capital raise (7/26)

Summit Corp. plc (Oxford, UK)

Private placement

16.8S

£1.35 ($2.2)

Summit raised $2.2M through a placement of 16.8M shares priced at 1 pence apiece; Singer Capital Markets and Hybridan LLP acted as joint placing agents (7/26)

Zogenix Inc. (San Diego)

Royalty financing agreement

N/A

$31 .5

Cowen Healthcare Royalty Partners II LP will invest $30M in Zogenix in exchange for 5%, stepping down to 0.5% and ending in 2018, royalties on worldwide net sales of approved migraine drug Sumavel DosePro, Phase III pain drug Zohydro and other Zogenix products; Cowen Royalty also will make an equity investment of $1.5 million in Zogenix common stock and will receive warrants exercisable for 10 years into 225,000 shares of Zogenix common stock at an exercise price of $9 per share (7/6)

Notes:

This chart does not include real estate or manufacturing plant financings, or debt deals done to replace existing debt. Loan money is included in the total only when it is drawn down, if disclosed.

** Denotes the date the item ran in BioWorld International. Currency conversions are based on exchange rates at the time of the deal.

The date indicated refers to the BioWorld Today issue in which the news item can be found.

N/A = Not applicable; ND = Not disclosed.